Search results
Results from the WOW.Com Content Network
According to the Global Initiative of Asthma (GINA), the guideline for anti-asthmatic treatment is divided into 5 levels according to asthma severity. [ 31 ] For newly diagnosed asthma patients, the 5 levels derived from the severity of asthma depend on the occurrence of symptoms and their frequencies.
Clenbuterol is approved for use in some countries as a bronchodilator for asthma. [medical citation needed]Clenbuterol is a β 2 agonist with some structural and pharmacological similarities to epinephrine and salbutamol, but its effects are more potent and longer-lasting as a stimulant and thermogenic drug.
GINA conducts continuous review of scientific publications on asthma and is a leader in disseminating information about the care of patients with asthma. [2] GINA publishes resources such as evidence-based guidelines for asthma management, and runs special events such as World Asthma Day. GINA's guidelines, revised each year, are used by ...
In medicine, a nebulizer (American English) [1] or nebuliser (British English) [2] is a drug delivery device used to administer medication in the form of a mist inhaled into the lungs. Nebulizers are commonly used for the treatment of asthma, cystic fibrosis, COPD and other respiratory diseases or disorders.
Doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in the treatment of chronic respiratory diseases such as asthma [1] and COPD. [2] Like theophylline, it is a xanthine derivative. [3] [4]
Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).
If you’ve tried every type of allergy medication or sinus treatment and haven’t found the relief that gets you back to 100%, ...
With the exception of formoterol, LABAs are not recommended for the treatment of acute asthma exacerbations because of their slower onset of action compared to salbutamol. Their long duration of action is due to the addition of a long lipophilic side-chain that binds to an exosite on adrenergic receptors.